These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 34724801)

  • 1. Anticoagulation Treatment and Outcomes of Venous Thromboembolism by Weight and Body Mass Index: Insights From the Veterans Health Administration.
    Perino AC; Fan J; Schmitt S; Guo JD; Hlavacek P; Din N; Kothari M; Pundi K; Russ C; Emir B; Turakhia MP
    Circ Cardiovasc Qual Outcomes; 2021 Nov; 14(11):e008005. PubMed ID: 34724801
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparing DOAC and warfarin outcomes in an obese population using the 'real-world' Michigan Anticoagulation Quality Improvement Initiative (MAQI
    Ardeshna N; Feldeisen T; Kong X; Haymart B; Kaatz S; Ali M; Barnes GD; Froehlich JB
    Vasc Med; 2024 Oct; 29(5):543-552. PubMed ID: 39177515
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness and Safety of Direct Oral Anticoagulants versus Warfarin in Obese Patients with Acute Venous Thromboembolism.
    Coons JC; Albert L; Bejjani A; Iasella CJ
    Pharmacotherapy; 2020 Mar; 40(3):204-210. PubMed ID: 31968126
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Warfarin Time in Therapeutic INR Range and Direct Oral Anticoagulant Adherence for Venous Thromboembolism Across the Spectrum of Weight and Body Mass Index: Findings from Veterans Health Administration.
    Din N; Fan J; Schmitt S; Guo JD; Hlavacek P; Pundi K; Russ C; Emir B; Turakhia MP; Perino AC
    Clin Appl Thromb Hemost; 2023; 29():10760296231152474. PubMed ID: 36694957
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Outcomes of Direct Oral Anticoagulants vs Warfarin for Extended Treatment of Venous Thromboembolism.
    Fang MC; Reynolds K; Fan D; Prasad PA; Sung SH; Portugal C; Garcia E; Go AS
    JAMA Netw Open; 2023 Aug; 6(8):e2328033. PubMed ID: 37581888
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Direct Oral Anticoagulants: Probability of Recurrent Venous Thromboembolism and Bleeding Risk in an Obese Population.
    Pilkerton CS; Adelman M; Crocetti E; Xiang J; Strick V; Ponte CD; Peckens S; Jackson BP; Whipp K; Ashcraft AM
    Ann Pharmacother; 2024 Aug; 58(8):781-789. PubMed ID: 37994550
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DOAC compared with warfarin for VTE in patients with obesity: a retrospective cohort study conducted through the VENUS network.
    Martin KA; Lancki N; Li C; Eyster ME; Sanfilippo K; Woller IA; Woller SC; Kreuziger LB; Rosovsky RP
    J Thromb Thrombolysis; 2023 May; 55(4):685-690. PubMed ID: 36757644
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rivaroxaban Versus Warfarin for Stroke Prevention and Venous Thromboembolism Treatment in Extreme Obesity and High Body Weight.
    Perales IJ; San Agustin K; DeAngelo J; Campbell AM
    Ann Pharmacother; 2020 Apr; 54(4):344-350. PubMed ID: 31672028
    [No Abstract]   [Full Text] [Related]  

  • 9. Safety and Efficacy of Direct Oral Anticoagulants vs Warfarin in Patients With Obesity and Venous Thromboembolism: A Retrospective Analysis.
    Tu ZH; Perez AD; Diaz TE; Loop MS; Clarke M
    Tex Heart Inst J; 2024 May; 51(1):. PubMed ID: 38748549
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anticoagulant therapies and outcomes in obese patients with acute venous thromboembolism.
    Quan S; Smith J; Wu C; Koshman SL; Nguyen B; Bungard TJ
    Thromb Res; 2020 Mar; 187():56-62. PubMed ID: 31955061
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A single center retrospective cohort study evaluating use of direct oral anticoagulants (DOACs) in morbidly obese veteran population.
    Patil T; Lebrecht M
    Thromb Res; 2020 Aug; 192():124-130. PubMed ID: 32473496
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of safety and efficacy outcomes of direct oral anticoagulants versus warfarin in normal and extreme body weights for the treatment of atrial fibrillation or venous thromboembolism.
    Novak AR; Shakowski C; Trujillo TC; Wright GC; Mueller SW; Kiser TH
    J Thromb Thrombolysis; 2022 Aug; 54(2):276-286. PubMed ID: 35689140
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative Effectiveness and Safety of Direct-acting Oral Anticoagulants and Warfarin in Patients with Venous Thromboembolism and Active Cancer: An Observational Analysis.
    Dawwas GK; Dietrich E; Smith SM; Davis K; Park H
    Clin Ther; 2020 Sep; 42(9):e161-e176. PubMed ID: 32768247
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Direct oral anticoagulants in the treatment of venous thromboembolism, with a focus on patients with pulmonary embolism: an evidence-based review.
    Gómez-Outes A; Suárez-Gea ML; Lecumberri R; Terleira-Fernández AI; Vargas-Castrillón E
    Vasc Health Risk Manag; 2014; 10():627-39. PubMed ID: 25404858
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Direct oral anticoagulants in the treatment of chronic thromboembolic pulmonary hypertension patients: A retrospective cohort study.
    Chong LT; Hu S; Guo TT; Gao X; Tan JS; Liu ZQ; Deng YR; Wei YX; Hua L
    Respir Med; 2024 Sep; 231():107722. PubMed ID: 38936635
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Case-fatality of recurrent venous thromboembolism and major bleeding associated with aspirin, warfarin, and direct oral anticoagulants for secondary prevention.
    Wu C; Alotaibi GS; Alsaleh K; Linkins LA; McMurtry MS
    Thromb Res; 2015 Feb; 135(2):243-8. PubMed ID: 25488466
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of direct oral anticoagulants across body mass index groups in patients with venous thromboembolism: a retrospective cohort design.
    Cardinal RM; D'Amico F; D'Addezio A; Dakers K; Castelli G
    J Thromb Thrombolysis; 2021 Aug; 52(2):567-576. PubMed ID: 33387202
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Direct Oral Anticoagulants in Antiphospholipid Syndrome-Associated Venous Thromboembolism: Real World Evidence.
    Hwang HG; Lee JH; Kim SA; Kim YK; Kim MS; Hong J; Yhim HY; Bang SM
    J Korean Med Sci; 2024 Sep; 39(36):e252. PubMed ID: 39315443
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of direct oral anticoagulants versus low molecular weight heparins for venous thromboembolism treatment in patients with gastrointestinal malignancies.
    Guan T; Laguna A; Soares A; Legasto CS; Block S; Saunders IM; Alvarez K; Pon T; Patel N; Mahajan A; Lee A
    J Thromb Thrombolysis; 2023 Oct; 56(3):439-446. PubMed ID: 37421494
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Which patients with unprovoked venous thromboembolism should receive extended anticoagulation with direct oral anticoagulants? A systematic review, network meta-analysis, and decision analysis.
    Djulbegovic M; Lee AI; Chen K
    J Eval Clin Pract; 2020 Feb; 26(1):7-17. PubMed ID: 31190408
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.